Is CYTK a good stock to buy? We came across a bullish thesis on Cytokinetics, Incorporated on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on CYTK. Cytokinetics, ...
Cytokinetics, Incorporated CYTK reported a net loss of $1.31 per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.02. In the year-ago quarter, the company ...
Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over ...
On Wednesday, Royalty Pharma plc (NASDAQ:RPRX) and Cytokinetics Incorporated (NASDAQ:CYTK) entered into a strategic funding collaboration providing capital to support the commercialization of ...
It has been about a month since the last earnings report for Cytokinetics (CYTK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
Cytokinetics, Incorporated CYTK reported a first-quarter 2026 loss of $1.67 per share, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company reported a loss of $1.36 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results